Cost-Effectiveness of Afatinib and Erlotinib as Second-Line Treatments for Advanced Squamous Cell Carcinoma of The Lung in China
Abstract
Authors
J Zhu M Ye J Fu B Wu Y Chu Y Zhao Y Zhang D Kuo B Su
J Zhu M Ye J Fu B Wu Y Chu Y Zhao Y Zhang D Kuo B Su
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now